BNP Paribas Financial Markets
ADAP

BNP Paribas Financial Markets’s Adaptimmune Therapeutics ADAP Stock Holding History

BNP Paribas Financial Markets’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-213
Closed -$28 – 5730
2025
Q3 		$28 Hold
213
– – ﹤0.01% 5492
2025
Q2 		$51 Hold
213
– – ﹤0.01% 5353
2025
Q1 		$42 Hold
213
– – ﹤0.01% 5295
2024
Q4 		$115 Hold
213
– – ﹤0.01% 5275
2024
Q3 		$202 Hold
213
– – ﹤0.01% 4041
2024
Q2 		$208 Hold
213
– – ﹤0.01% 3931
2024
Q1 		$337 Sell
213
-1,949
-90% -$2.35K ﹤0.01% 3918
2023
Q4 		$1.71K Sell
2,162
-1,891
-47% -$1.07K ﹤0.01% 3815
2023
Q3 		$3.16K Buy
4,053
+2,339
+136% +$1.96K ﹤0.01% 3693
2023
Q2 		$1.58K Buy
1,714
+595
+53% +$709 ﹤0.01% 3738
2023
Q1 		$1.22K Buy
1,119
+182
+19% +$282 ﹤0.01% 3669
2022
Q4 		$1.37K Buy
937
+515
+122% +$834 ﹤0.01% 3771
2022
Q3 		$454 Sell
422
-1,670
-80% -$3.07K ﹤0.01% 4532
2022
Q2 		$3.56K Buy
+2,092
New +$3.59K ﹤0.01% 3847
2019
Q2 		– Sell
-3,937
Closed -$16.9K – 4537
2019
Q1 		$16.9K Hold
3,937
– – ﹤0.01% 3942
2018
Q4 		$22.6K Sell
3,937
-6,365
-62% -$47K ﹤0.01% 3068
2018
Q3 		$140K Hold
10,302
– – ﹤0.01% 2570
2018
Q2 		$122K Buy
+10,302
New +$128K ﹤0.01% 2682

Other funds holding ADAP

JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
EF
Empirical Finance Havertown, Pennsylvania $2.13B AUM 29.56% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

BNP Paribas Financial Markets's ADAP Position: Q4 2025 in Review

BNP Paribas Financial Markets sold out of Adaptimmune Therapeutics (ADAP) in Q4 2025, closing a stake of 213 shares — an estimated $28 sold.

BNP Paribas Financial Markets first reported a position in ADAP in Q2 2018 and held it in 18 quarters. The position peaked at $140K in Q3 2018. 10 funds tracked by Wall St. Rank hold ADAP as of Q4 2025.

  • BNP Paribas Financial Markets reported no remaining Adaptimmune Therapeutics position as of Q4 2025 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 213 Adaptimmune Therapeutics shares in Q4 2025, an estimated $28.
  • BNP Paribas Financial Markets first reported a position in Adaptimmune Therapeutics in Q2 2018 and held it in 18 quarters.
  • BNP Paribas Financial Markets's Adaptimmune Therapeutics position peaked at $140K in Q3 2018.
  • 10 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2025.

Based on BNP Paribas Financial Markets's 13F filing for Q4 2025, filed 10 Feb 2026.